ASGPR: A Key Receptor in Liver Biology—From Physiological Functions to Clinical Translation with ANT BIO PTE. LTD.

1. Concept

The asialoglycoprotein receptor (ASGPR), a liver-specific endocytic receptor first identified by Ashwell and colleagues, is a critical mediator of glycoprotein metabolism and liver homeostasis. Expressed predominantly on the sinusoidal surface of hepatocytes, ASGPR belongs to the C-type lectin superfamily and functions as a heterooligomeric complex. Its core biological role is to recognize and clear circulating asialoglycoproteins—glycoproteins with terminal β-1,4-linked galactose or N-acetylgalactosamine residues—via receptor-mediated endocytosis and lysosomal degradation. Beyond its physiological function in glycoprotein clearance, ASGPR is closely intertwined with the pathogenesis of liver diseases (e.g., viral hepatitis, alcoholic liver disease, hepatocellular carcinoma) and has emerged as a pivotal target for liver-directed drug and gene delivery. Its unique liver tropism, high expression on hepatocytes, and efficient endocytic capacity make it a versatile tool for both basic liver research and translational applications in diagnosis and therapy.

2. Research Frontiers

Recent advances in liver biology and translational research have expanded the understanding and application of ASGPR, with key frontiers including:

• Molecular mechanisms of viral entry: ASGPR has been identified as a critical host receptor for hepatitis B virus (HBV) entry, mediating viral attachment via interaction with the HBV preS1 domain. Research is now focused on deciphering the structural basis of this interaction to develop novel antiviral therapeutics that block viral-hepatocyte binding.
• Liver disease diagnostics: ASGPR expression and activity are emerging as robust biomarkers for hepatocyte function. Studies explore the use of ASGPR-targeted imaging agents to assess liver reserve function, predict surgical outcomes, and monitor disease progression in chronic liver disorders.
• Targeted drug/gene delivery: ASGPR’s ability to internalize ligand-conjugated molecules has driven the development of liver-specific delivery systems. Current research focuses on optimizing formulations (e.g., GalNAc-conjugated siRNAs, antibody-drug conjugates, recombinant immunotoxins) to enhance targeting efficiency and reduce off-tissue toxicity.
• Role in liver injury and cancer: Investigations into ASGPR’s protective effects against T cell-mediated liver injury and its dysregulation in hepatocellular carcinoma (HCC) are ongoing, with potential implications for developing new therapeutic strategies to modulate ASGPR function in these conditions.

3. Research Significance

ASGPR research holds profound significance for basic biology, clinical diagnosis, and therapeutic development:

• Basic liver physiology: Elucidating ASGPR’s structure and function provides critical insights into hepatocyte-specific endocytosis, glycoprotein metabolism, and liver homeostasis, serving as a model system for understanding receptor-mediated transport.
• Liver disease diagnosis: ASGPR expression levels correlate with hepatocyte integrity—dysregulation is observed in hepatitis, alcoholic liver disease, and HCC. This makes ASGPR a promising biomarker for non-invasive liver function assessment and disease staging.
• Antiviral therapy: Targeting ASGPR to block HBV entry offers a novel approach to treating chronic hepatitis B, addressing the unmet need for therapies that prevent viral infection at the host cell interface.
• Targeted drug delivery: ASGPR-mediated delivery systems enable precise targeting of hepatocytes, improving the efficacy and safety of drugs for liver diseases (e.g., HCC, non-alcoholic fatty liver disease) and gene therapies for inherited metabolic disorders.

4. Relevant Mechanisms, Research Methods, and Product Applications

Core Mechanisms

1. Ligand Recognition and Endocytosis: ASGPR’s carbohydrate recognition domain (CRD) specifically binds to terminal galactose or N-acetylgalactosamine residues on asialoglycoproteins. This binding triggers receptor clustering, internalization via clathrin-coated vesicles, and lysosomal degradation of the ligand-receptor complex—facilitating efficient clearance of circulating glycoproteins.
2. Heterooligomeric Complex Function: ASGPR functions as a complex of two subunits (H1/ASGR1 and H2/ASGR2). The H1 subunit is essential for ligand binding and surface localization of the complex, while the H2 subunit modulates stability and trafficking. Absence of either subunit abrogates functional receptor activity.
3. Viral Entry Mediation: HBV uses the ASGPR H1 subunit’s CRD as a binding site for its preS1 domain, enabling viral internalization into hepatocytes. Blocking this interaction inhibits viral entry, highlighting ASGPR’s role as a therapeutic target for HBV.
4. Liver-Protective Effects: ASGPR deficiency enhances sensitivity to T cell-mediated liver injury, suggesting a role in regulating immune responses and protecting hepatocytes from inflammatory damage.

Key Research Methods

• Structural Biology Techniques: X-ray crystallography and cryo-electron microscopy to characterize the CRD’s structure and ligand-binding interface.
• Immunodetection Assays: Western blotting, immunofluorescence, and flow cytometry to quantify ASGPR expression and localization in hepatocytes and tissue samples.
• Ligand Binding and Endocytosis Assays: In vitro assays using labeled asialoglycoproteins (e.g., asialo serum orosomucoid, ASOR) to measure ASGPR binding affinity and internalization efficiency.
• Viral Entry Assays: Cell-based models (e.g., HepG2 cells) to evaluate the role of ASGPR in HBV entry and test inhibitory compounds.
• Targeted Delivery Validation: In vitro and in vivo studies to assess the liver tropism of ASGPR-targeted drug/gene delivery systems.

Product Applications by ANT BIO PTE. LTD.

ANT BIO PTE. LTD.’s specialized product portfolio—STARTER antibodies, UA recombinant proteins, and Absin kits—provides indispensable tools to advance ASGPR research across basic and translational applications:

• UA Recombinant Proteins: The "Biotinylated ASGR1/ASGPR1 His&Avi Tag Protein, Human (Catalog No.: UA010845)" is expressed in HEK293 cells, ensuring native folding and functional CRD. Key applications include:
• Ligand-binding assays to study ASGPR’s interaction with asialoglycoproteins or viral proteins (e.g., HBV preS1).
• Validation of ASGPR-targeted delivery systems (e.g., GalNAc-conjugated molecules) for specificity and binding affinity.
• Structural biology studies to resolve ASGPR-ligand complexes.
• STARTER Antibodies: High-specificity antibodies such as "ASGPR1 Recombinant Rabbit mAb (S-R292) (Catalog No.: S0B0423)" and "ASGR1 Rabbit Polyclonal Antibody (Catalog No.: S0B1374)" enable:
• Specific detection of ASGPR in Western blotting, immunofluorescence, and flow cytometry for expression profiling in normal and diseased liver tissues.
• Immunoprecipitation of ASGPR to investigate protein-protein interactions (e.g., with HBV preS1 or intracellular signaling molecules).
• Identification and sorting of ASGPR-expressing hepatocytes for functional assays.
• Absin Kits & General Reagents: Specialized kits (e.g., endocytosis assay kits, ligand-binding assay kits) and high-purity reagents (e.g., labeled ASOR, lysosomal markers) support:
• Quantitative measurement of ASGPR-mediated endocytosis and ligand degradation.
• Validation of ASGPR-targeted drug delivery efficiency.
• Standardization of immunoassays for ASGPR expression in clinical samples.

5. Brand Mission

At ANT BIO PTE. LTD., our mission is to empower global life science researchers, clinicians, and drug developers with high-quality, innovative, and reliable research tools that accelerate breakthroughs in liver biology and translational medicine. We are committed to advancing the fields of hepatology, virology, and targeted therapy by delivering specialized products—including antibodies (STARTER), recombinant proteins (UA), and kits & general reagents (Absin)—that meet the rigorous demands of cutting-edge research and clinical translation. Backed by 15 years of expertise in antibody and protein development, and certifications including EU 98/79/EC, ISO9001, and ISO13485, we strive to bridge the gap between basic research and clinical application. Our dedication to excellence ensures that researchers worldwide have access to the tools they need to unravel the complexities of ASGPR function, validate novel diagnostic biomarkers, and develop life-changing therapies for liver diseases.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.